Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

3(50.0%)

Phase 1

2(33.3%)

Phase 2

1(16.7%)

6Total

N/A(3)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT04101292Not ApplicableWithdrawn

Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours (Elios-Color-on-Specimen)

Role: collaborator

NCT02899442Not ApplicableCompleted

Cardiovascular Risk Prevention Among Night Workers

Role: collaborator

NCT04589884Terminated

Intraoperative EXamination Using MAChine-learning-based HYperspectral for diagNosis & Autonomous Anatomy Assessment

Role: collaborator

NCT03386929Phase 1Terminated

Survival Prolongation by Rationale Innovative Genomics

Role: collaborator

NCT02570516Not ApplicableCompleted

NBI Versus Indigo Carmine During Colonoscopy in Lynch Syndrome

Role: collaborator

NCT02364206Phase 1Completed

Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

Role: collaborator

NCT02322853Phase 2Terminated

A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

Role: collaborator

All 7 trials loaded